Kedem Pharmaceuticals Inc. - FORM 8-K - EX-16.1 - LETTER FROM UHY LDMB ADVISORS INC. TO THE SECURITIES AND EXCHANGE COMMISSION DATED SEPTEMBER 27, 2011 - September 27, 2011

Attached files

file filename
8-K - FORM 8-K - Kedem Pharmaceuticals Inc.ghlv-8k.htm
EX-3.10 - ARTICLES OF MERGER FILED WITH THE NEVADA SECRETARY OF STATE ON SEPTEMBER 23, 2011 - Kedem Pharmaceuticals Inc.ex3-10.htm
EX-3.11 - CERTIFICATE OF CHANGE FILED WITH THE NEVADA SECRETARY OF STATE ON SEPTEMBER 26, 2011 - Kedem Pharmaceuticals Inc.ex3-11.htm
 
 
 September 27, 2011  
n    South Surrey
1688 – 152nd Street
Suite 306
South Surrey, BC
Canada  V4A 4N2
 
Phone  604 538 1611
Fax      604 538 1633
 
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C.  20549
U.S.A.

Dear Ladies and Gentlemen:

Re: Kedem Pharmaceuticals Inc. (the “Company”)

This letter confirms that we have reviewed Item 4.01, Changes in Registrant’s Certifying Accountant, of the Company’s Form 8-K dated September 27, 2011 and are in agreement with the statements made therein as it pertains to our firm.
 
Yours very truly,

/s/ UHY LDMB ADVISORS INC.
UHY LDMB ADVISORS INC.
CHARTERED ACCOUNTANTS
 
 


 


Kedem Pharmaceuticals Inc. Reports